The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT06015243 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Rhinosinusitis With Nasal Polyps

Interventions

DRUG: GR1802 injection

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.